These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10594481)

  • 21. Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women.
    Dias AR; de Mello NR; Eluf Gebara OC; Nussbacher A; Wajngarten M; Petti DA
    Climacteric; 2008 Oct; 11(5):390-6. PubMed ID: 18781483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.
    Freedman M; San Martin J; O'Gorman J; Eckert S; Lippman ME; Lo SC; Walls EL; Zeng J
    J Natl Cancer Inst; 2001 Jan; 93(1):51-6. PubMed ID: 11136842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes.
    Van Pelt RE; Gozansky WS; Wolfe P; Kittelson JM; Jankowski CM; Schwartz RS; Kohrt WM
    Obesity (Silver Spring); 2014 Apr; 22(4):1024-31. PubMed ID: 24311443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemoprevention of breast cancer with selective oestrogen-receptor modulators.
    Jordan VC
    Nat Rev Cancer; 2007 Jan; 7(1):46-53. PubMed ID: 17186017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The search for the ideal SERM.
    Arun B; Anthony M; Dunn B
    Expert Opin Pharmacother; 2002 Jun; 3(6):681-91. PubMed ID: 12036407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological significance of interventions that change breast density.
    Chlebowski RT; McTiernan A
    J Natl Cancer Inst; 2003 Jan; 95(1):4-5. PubMed ID: 12509389
    [No Abstract]   [Full Text] [Related]  

  • 27. Selective estrogen receptor modulators.
    Kearney CE; Purdie DW
    Climacteric; 1998 Jun; 1(2):143-7. PubMed ID: 11907917
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.
    Sporn MB; Dowsett SA; Mershon J; Bryant HU
    Clin Ther; 2004 Jun; 26(6):830-40. PubMed ID: 15262454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells.
    Boostanfar R; Amezcua CA; Tourgeman DE; Roy S; Felix JC; Stanczyk FZ
    Fertil Steril; 2003 Jan; 79(1):223-5. PubMed ID: 12524096
    [No Abstract]   [Full Text] [Related]  

  • 30. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
    Saitta A; Altavilla D; Cucinotta D; Morabito N; Frisina N; Corrado F; D'Anna R; Lasco A; Squadrito G; Gaudio A; Cancellieri F; Arcoraci V; Squadrito F
    Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1512-9. PubMed ID: 11557681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Rizos D; Coutoukos J; Creatsas G
    Fertil Steril; 2003 Feb; 79(2):455-6. PubMed ID: 12568869
    [No Abstract]   [Full Text] [Related]  

  • 32. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene.
    Thiebaud D; Secrest RJ
    Reprod Fertil Dev; 2001; 13(4):331-6. PubMed ID: 11800172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
    Kobayashi H; Hamaya E
    Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):37-48. PubMed ID: 15738620
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk.
    Cerquetani E; Vitale C; Mercuro G; Fini M; Zoncu S; Rosano GM
    Gynecol Endocrinol; 2004 Jun; 18(6):291-8. PubMed ID: 15497491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracellular matrix integrity: a possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens?
    Cox DA; Helvering LM
    Mol Cell Endocrinol; 2006 Mar; 247(1-2):53-9. PubMed ID: 16426741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective estrogen receptor modulators and postmenopausal women's health.
    Hol T; Cox MB; Bryant HU; Draper MW
    J Womens Health; 1997 Oct; 6(5):523-31. PubMed ID: 9356975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB
    Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Menopause. HRT: looking for something better.
    Harv Health Lett; 2002 May; 27(7):5. PubMed ID: 12034554
    [No Abstract]   [Full Text] [Related]  

  • 39. Estrogen, selective estrogen receptor modulators and now mechanism-specific ligands of the estrogen or androgen receptor?
    Khosla S
    Trends Pharmacol Sci; 2003 Jun; 24(6):261-3. PubMed ID: 12823947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats.
    Gogos A; van den Buuse M
    Schizophr Res; 2015 Nov; 168(3):634-9. PubMed ID: 25979306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.